Search results
What You Need to Know About Humira's Low-Cost Competitors
Verywell Health via Yahoo News· 9 months agoAt least nine Humira biosimilars are coming to market, along with promises of lower costs for...
AbbVie's Humira gets a U.S. rival, but costs could stay high
Reuters via Yahoo Finance· 1 year agoU.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug...
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance
Associated Press via Yahoo News· 11 months agoPatients who take the autoimmune disease treatment Humira may see some price relief when several...
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Investor's Business Daily· 1 year agoAbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar...
Analysis-New Humira rivals likely to hit US market with small discounts in July
Reuters via Yahoo News· 11 months agoAt least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling...
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
Reuters via AOL· 5 months agoCVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira...
Do Humira Biosimilars Threaten AbbVie's Dividend?
Motley Fool· 1 year agoPharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters via Yahoo Finance· 1 month agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
Boehringer Ingelheim to lay off staff amid biosimilar challenges
BioPharma Dive via Yahoo Finance· 2 months agoThe German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a...
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Motley Fool· 1 year agoLast week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...